Asymptomatic Thrombocytopenia After Nintedanib Initiation in a Patient with Progressive Pulmonary Fibrosis: a Case Report and Review of Literature

Overview

Journal J Med Case Rep

Publisher Biomed Central

Specialty General Medicine

Date 2024 Sep 28

PMID 39342394

Authors

Xinxin Zhang

Kan Zhang

Nannan Zhao

Na Xi

Tiemei Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Nintedanib is a primary antifibrosing medication available for idiopathic pulmonary fibrosis, systemic sclerosis-interstitial lung disease, and progressive pulmonary fibrosis, with scattered report of drug-induced thrombocytopenia.

Case Report: A 60-year-old Asian male with no history of thrombocytopenia was administered with nintedanib to treat progressive pulmonary fibrosis. The platelet count dropped rapidly after introduction of nintedanib and resolved gradually by withdrawal of the medication along with thrombopoietin receptor agonist.

Conclusion: Based on experience from the limited reports, nintedanib-induced thrombocytopenia is typically reversible and manageable. Close monitoring of platelet counts in patients receiving this medication should be warranted.

References

Grzesk G, Wozniak-Wisniewska A, Blazejewski J, Gorny B, Wolowiec L, Rogowicz D . The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications. Int J Mol Sci. 2021; 22(1). PMC: 7795697. DOI: 10.3390/ijms22010282. View

Jansen A, Spaan T, Low H, Di Iorio D, van den Brand J, Tieke M . Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity. Blood Adv. 2020; 4(13):2967-2978. PMC: 7362372. DOI: 10.1182/bloodadvances.2020001640. View

Mistry R, Rawson T, Troise O, Mughal N, Moore L, Hughes S . Haematological and hepatic adverse effects of ceftriaxone in ambulatory care: a dual-centre retrospective observational analysis of standard vs high dose. BMC Infect Dis. 2022; 22(1):959. PMC: 9789631. DOI: 10.1186/s12879-022-07925-y. View

Qureshi Z, Altaf F, Khanzada M, Thet A, Espinosa L . Ceftriaxone-Induced Thrombotic Thrombocytopenic Purpura Treated Successfully With Plasmapheresis and Eculizumab: A Rare Case Report. Cureus. 2023; 15(11):e48898. PMC: 10653270. DOI: 10.7759/cureus.48898. View

Marini I, Uzun G, Jamal K, Bakchoul T . Treatment of drug-induced immune thrombocytopenias. Haematologica. 2022; 107(6):1264-1277. PMC: 9152960. DOI: 10.3324/haematol.2021.279484. View

Dumic I, Charokopos A, Parmar A, Grant C, Cosiquien R, da Silva M . Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis. Medicina (Kaunas). 2023; 59(5). PMC: 10224178. DOI: 10.3390/medicina59050999. View

Giannini M, Grignaschi S, Fornaro M, Caporali R, Locatelli F, Zanframundo G . Thrombocytopenia in idiopathic inflammatory myopathies: a case series analysis. Clin Exp Rheumatol. 2019; 38(5):891-895. View

Richeldi L, Costabel U, Selman M, Kim D, Hansell D, Nicholson A . Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365(12):1079-87. DOI: 10.1056/NEJMoa1103690. View

Avecilla S, Hattori K, Heissig B, Tejada R, Liao F, Shido K . Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004; 10(1):64-71. DOI: 10.1038/nm973. View

10.

Nakamura M, Okamoto M, Fujimoto K, Ebata T, Tominaga M, Nouno T . A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world. Ann Transl Med. 2019; 7(12):262. PMC: 6614312. DOI: 10.21037/atm.2019.05.33. View

11.

Mitta A, Curtis B, Reese J, George J . Drug-induced thrombocytopenia: 2019 Update of clinical and laboratory data. Am J Hematol. 2018; 94(3):E76-E78. DOI: 10.1002/ajh.25379. View

12.

Flaherty K, Wells A, Cottin V, Devaraj A, Walsh S, Inoue Y . Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18):1718-1727. DOI: 10.1056/NEJMoa1908681. View